Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  26.00 2.78% 960.00 920.00 1,000.00 960.00 960.00 960.00 4,975 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.6 -16.0 - 692

Renalytix AI PLC Notice of Results

23/02/2021 7:00am

UK Regulatory (RNS & others)


Renalytix Ai (LSE:RENX)
Historical Stock Chart


From Feb 2021 to Apr 2021

Click Here for more Renalytix Ai Charts.

TIDMRENX

RNS Number : 9649P

Renalytix AI PLC

23 February 2021

Renalytix AI plc

("RenalytixAI" or the "Company")

RenalytixAI to announce Financial Results for six and three months ended December 31, 2020

NEW YORK, February 23, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), the artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care , announces that it will report its financial results for the six and three months ended December 31, 2020 on Tuesday, March 2, 2021.

Analyst conference call

The Company will hold an analyst conference call at 8:30 a.m. (EST) / 1:30 p.m. (GMT) p.m. on Tuesday, March 2, 2021. James McCullough, CEO and O. James Sterling, CFO will discuss the financial results and provide a corporate update.

Conference Call Details

US/CANADA Participant Toll-Free Dial-In Number: (833) 614-1551

US/CANADA Participant International Dial-In Number: (914) 987-7290

United Kingdom Dial-In Number: 08000 288 438

United Kingdom, London Dial-In Number: 020 3107 0289

Conference ID: 8982902

   Webcast Registration link:   https://edge.media-server.com/mmc/p/vmhxbo58 

For further information, please contact:

 
Renalytix AI plc                         www.renalytixai.com 
James McCullough, CEO                        Via Walbrook PR 
 
Stifel (Nominated Adviser, Joint Broker   Tel: 020 7710 7600 
 ) 
Alex Price / Nicholas Moore 
 
Investec Bank plc (Joint Broker)          Tel: 020 7597 4000 
Gary Clarence / Daniel Adams 
 
 

UK Investor Contact:

 
Walbrook PR Limited        Tel: 020 7933 8780 or renalytix@walbrookpr.com 
Paul McManus / Lianne Cawthorne            Mob: 07980 541 893 / 07584 391 
                                                                      303 
 
 

US Investor Contact:

 
Gilmartin Group                                 i nvestors@renalytixai.com 
Carrie Mendivil / Mary Kate McDonough                         415-937-5405 
 
 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com .

Forward Looking Statements

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should, " "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue, " "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSEAEDEEFSEEE

(END) Dow Jones Newswires

February 23, 2021 02:00 ET (07:00 GMT)

1 Year Renalytix Ai Chart

1 Year Renalytix Ai Chart

1 Month Renalytix Ai Chart

1 Month Renalytix Ai Chart
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210421 15:07:30